{
    "title": "Sanofi profit gain beats market view on bestseller drug Dupixent",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-10762103/Sanofi-profit-gain-beats-market-view-bestseller-drug-Dupixent.html",
    "date": "2022-04-28",
    "keywords": [
        "group",
        "drug",
        "dupixent",
        "trial",
        "burger",
        "healthcare",
        "growth",
        "analyst",
        "area",
        "ms",
        "copd",
        "roche",
        "race",
        "year",
        "vaccine",
        "rebound",
        "demand",
        "firstquarter",
        "business",
        "income",
        "interest",
        "tax",
        "estimate",
        "companys",
        "revenue",
        "eczema",
        "treatment",
        "consensus",
        "dermatitis",
        "asthma",
        "drugmaker",
        "patient",
        "recruitment",
        "russia",
        "belarus",
        "attack",
        "study",
        "sclerosis",
        "disease",
        "timing",
        "approval",
        "war",
        "development",
        "generation",
        "industry",
        "europe",
        "novartis",
        "merck",
        "btk",
        "turn",
        "sanofi",
        "month",
        "regeneron",
        "target",
        "use",
        "lung",
        "effect",
        "volunteer",
        "consumer",
        "unit",
        "market",
        "surge",
        "cough",
        "thursday",
        "share",
        "doubledigit",
        "percentage",
        "partner",
        "glaxosmithkline",
        "nextgeneration",
        "booster",
        "protection",
        "concern",
        "quarter",
        "jason"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}